{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T17:00:57Z","timestamp":1771779657704,"version":"3.50.1"},"reference-count":26,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["aspenjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Parenter Enteral Nutr"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Iron supplementation is required for pediatric patients with intestinal failure (IF). There is a paucity of literature on optimal iron formulation and outcomes in this patient population that requires ongoing supplementation. The aim of this study was to assess outcomes in pediatric patients with IF receiving iron sucrose (IS) vs ferric carboxymaltose (FCM) iron infusions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a single\u2010center observational cohort study of pediatric patients with IF requiring ongoing intravenous iron supplementation. Patients were transitioned from IS to FCM as iron therapy. Longitudinal linear mixed\u2010effects models and generalized estimating equations were used to compare outcomes, including hematologic, iron, and growth parameters for 12\u2010month treatment duration on each iron formulation. Adverse effects were descriptively summarized.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty\u2010three patients were included. Sixteen received IS and later switched to FCM, five received IS only, and two received FCM only. Most patients' etiology of IF was short bowel syndrome (FCM: 81%, IS: 83%). No differences were seen over time for iron, hematologic, and growth metrics between IS and FCM. The median number of infusions over 12 months for those taking IS was 15 (interquartile range [IQR]\u2009=\u200913\u201326) and 2 for FCM (IQR\u2009=\u20091\u20132). Asymptomatic hypophosphatemia was noted in both groups. Similar central line\u2013associated bloodstream infection rates were noted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>IS and FCM infusions both maintained hematologic and iron parameters with no significant difference noted between the two types of iron, though the number of FCM infusions was significantly less. No significant adverse effects were noted.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jpen.2412","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T07:53:20Z","timestamp":1653551600000},"page":"1578-1584","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Analysis of transition from intravenous iron sucrose to ferric carboxymaltose infusions in pediatric patients with intestinal failure"],"prefix":"10.1002","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-0075","authenticated-orcid":false,"given":"Tanyaporn K.","family":"Kaenkumchorn","sequence":"first","affiliation":[{"name":"Division of Pediatric Gastroenterology, Hepatology, and Nutrition Children's Hospital of Los Angeles  Los Angeles California USA"},{"name":"Department of Pediatrics, School of Medicine University of Southern California  Los Angeles California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice E.","family":"Rosete","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Seattle Children's Hospital  Seattle Washington USA"},{"name":"School of Pharmacy University of Washington  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Carlin","sequence":"additional","affiliation":[{"name":"Biostatistics, Epidemiology, and Analytics in Research Seattle Children's Research Institute  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiho","family":"Fukasawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Seattle Children's Hospital  Seattle Washington USA"},{"name":"School of Pharmacy University of Washington  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5949-7363","authenticated-orcid":false,"given":"Simon P.","family":"Horslen","sequence":"additional","affiliation":[{"name":"Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Pittsburgh University of Pittsburg Medical Center  Pittsburgh Pennsylvania USA"},{"name":"Department of Pediatrics, School of Medicine University of Pittsburgh, Pittsburgh  Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Wendel","sequence":"additional","affiliation":[{"name":"Division of Pediatric Gastroenterology and Hepatology Seattle Children's Hospital  Seattle Washington USA"},{"name":"Department of Pediatrics, School of Medicine University of Washington  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,6,21]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"405","volume-title":"Pediatric Gastroinstestinal and Liver Disease","author":"Wyllie R","year":"2016"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1067\/j.cpsurg.2011.10.002"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2016.02.011"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010-2576"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2016.09.053"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.107.6.1381"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1203\/01.PDR.0000047657.23156.55"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-015-0361-z"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/1747-0080.12355"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/0148607117690528"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/169107"},{"key":"e_1_2_8_13_1","unstructured":"Iron sucrose. Lexicomp. Wolters Kluwer. Accessed May 10 2021.https:\/\/online.lexi.com\/lco"},{"key":"e_1_2_8_14_1","unstructured":"Ferric carboxymaltose. Lexicomp. Wolters Kluwer. Accessed May 10 2021.https:\/\/online.lexi.com\/lco"},{"key":"e_1_2_8_15_1","unstructured":"Injectafer. Package insert. American Regent Inc;2020."},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01744.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X15616577"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-018-1045-8"},{"issue":"1","key":"e_1_2_8_19_1","first-page":"A172","article-title":"5PSQ\u2010017 safety of intravenous ferric carboxymaltose in treatment of iron deficiency in children under 2 years with intestinal failure","volume":"25","author":"Athiana I","year":"2018","journal-title":"Eur J Hosp Pharm"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12289"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/0148607114525210"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2018.06.949"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000003003"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-14-184"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.22450"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/apa.15178"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2019-101242"}],"container-title":["Journal of Parenteral and Enteral Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jpen.2412","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jpen.2412","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/aspenjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jpen.2412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T09:40:32Z","timestamp":1760866832000},"score":1,"resource":{"primary":{"URL":"https:\/\/aspenjournals.onlinelibrary.wiley.com\/doi\/10.1002\/jpen.2412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,21]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1002\/jpen.2412"],"URL":"https:\/\/doi.org\/10.1002\/jpen.2412","archive":["Portico"],"relation":{},"ISSN":["0148-6071","1941-2444"],"issn-type":[{"value":"0148-6071","type":"print"},{"value":"1941-2444","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,21]]},"assertion":[{"value":"2022-03-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}